Exelixis EXEL
NASDAQ EXEL
$64.58 +0.19 (+0.30%)
At close: Oct 21, 2026 · 4:00 PM EDT

Exelixis (EXEL) Long-Term Debt Repayments (2016 - 2020)

Updated

Exelixis' Long-Term Debt Repayments came in at -$34,000 for Q4 2020.

Analysis

Exelixis (EXEL) Long-Term Debt Repayments (2016 - 2020) Analysis & Trends

For FY2017, Exelixis' Long-Term Debt Repayments was $185.79 million.

  • Long-Term Debt Repayments carries a four-year compound annual growth rate of 107.6% (FY2013 to FY2017).
  • Going back by year, Long-Term Debt Repayments was $575,000 in FY2016 and $10 million in FY2013.
  • Business Quant data shows EXEL's Long-Term Debt Repayments at $12,000 (Q3 2020), $11,000 (Q2 2020) and $11,000 (Q1 2020) in the three quarters before Q4 2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Repayment (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 873.00 Mn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 1.00 Mn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 2.00 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 5.00 Mn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 20.00 Mn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 2.46 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn -
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 17.00 Mn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -
10 Exelixis 16.19 Bn 12.53 Bn 608.03 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jan 3, 2020 -34,000.00
Sep 27, 2019 12,000.00
Jun 28, 2019 11,000.00
Mar 29, 2019 11,000.00
Jun 30, 2017 105.79 Mn
Mar 31, 2017 80.00 Mn
Dec 30, 2016 575,000.00
API Access

Exelixis Long-Term Debt Repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-repayments&ticker=EXEL&period=max&api_key=YOUR_API_KEY